J&J CFO Joseph Wolk Said Amgen Settlement Gives Co More Confidence About Hitting Its 2025 $57B Target For Pharma Sales
Portfolio Pulse from Charles Gross
In a recent interview with Reuters, Johnson & Johnson's CFO, Joseph Wolk, stated that the company's settlement with Amgen gives them more confidence about achieving their 2025 target of $57 billion in pharmaceutical sales.
July 20, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The settlement with Amgen is expected to boost Johnson & Johnson's confidence in achieving their 2025 target for pharmaceutical sales.
The settlement with Amgen is likely to have a positive impact on J&J's future revenues, which could potentially boost its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Amgen's settlement with Johnson & Johnson could potentially impact the company's financials.
The details of the settlement were not disclosed in the news, making it difficult to predict the exact impact on Amgen's financials and stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50